Antibiotics: Officially Encouraged, Increasingly Precise, Still Risky
This article was originally published in Start Up
Executive Summary
Anti-infective start-ups getting funded these days say they can boost the odds of clinical success, and reduce the cost of achieving it. Profiles of EnBiotix, Nosopharm, and Spero Therapeutics.
You may also be interested in...
Pipeline Update: New Antifungals Sprout In Warmer Regulatory Climate
Candidates from Cidara, Scynexis, Viamet and more featured in a symposium at the ICAAC/ICC meeting in September.
Merck’s Bezlotoxumab C. Difficile Data Pave Way For Antibodies
Company readies regulatory filings for bezlotoxumab as a monotherapy in preventing C. difficile, following presentation of positive MODIFY I and II data at the ICAAC meeting in San Diego.
Point-Of-Care Testing Stirs Anew
Point-of-care diagnostics are back in favor with investors who believe market forces and technological advances are finally converging in ways that invite success and this time, they may be right. Profiles of GeneWEAVE, HiberGene, Spectromics, and Xagenic.